Analysis of Molecular and Clinical Parameters of 4-year Adalimumab Therapy in Psoriatic Patients

Overview

Journal Postepy Dermatol Alergol

Publisher Termedia

Specialty Allergy & Immunology

Date 2020 Nov 26

PMID 33240014

Citations 2

Authors

Dominika Wcislo-Dziadecka

Beniamin Grabarek

Celina Kruszniewska-Rajs

Andrzej Swinarew

Krzysztof Jasik

Beata Rozwadowska

Agata Krawczyk

Affiliations

Soon will be listed here.

Abstract

Introdcution: Through interaction with receptors TNFR1 and TNFR2, TNF-α activates a signal path, which exacerbates an inflammatory process, constituting an inseparable element of psoriasis.

Aim: To evaluate changes in the expression of α, during the 4-year-long adalimumab therapy in psoriatic patients, searching for the correlation between molecular and clinical markers. In addition, the role of miRNAs was analysed.

Material And Methods: Whole blood and serum samples of psoriatic patients treated with adalimumab constituted material for the study. Changes in the expression of α and its receptors were evaluated with the use of the RTqPCR method and MALDI ToF mass spectroscopy, PASI, BSA, DAS28 indexes were used for the clinical analysis of the patients, while the role of miRNA molecules was determined basing on microrna.org database.

Results: Different TNF-α expression patterns were determined in patients with observed resistance to the medicine. We found that there is a correlation between the molecular markers of an inflammatory process and the clinical indexes. The bioinformatic analysis indicates the potential role of miRNAs in the regulation of expression of the analysed genes. Changes in the profile of TNF-α during adalimumab therapy are significantly determined by the individual variability and susceptibility to the biological medicine or its loss.

Conclusions: TNF-α seems to be a useful marker to evaluate the efficacy of therapy and occurring resistance to the medicine. A complex mechanism for the regulation of the analysed gene expression was underlined, which involved the potential role of miRNAs.

Citing Articles

Biomarkers in psoriatic arthritis: A meta-analysis and systematic review.

Wirth T, Balandraud N, Boyer L, Lafforgue P, Pham T Front Immunol. 2022; 13:1054539.

PMID: 36532039 PMC: 9749424. DOI: 10.3389/fimmu.2022.1054539.

The Gene as Potential Diagnostic Marker in Monitoring Adalimumab Therapy of Psoriatic Arthritis.

Krawczyk A, Strzalka-Mrozik B, Juszczyk K, Kimsa-Dudek M, Wcislo-Dziadecka D, Gola J Curr Pharm Biotechnol. 2022; 24(2):330-340.

PMID: 35762548 DOI: 10.2174/1389201023666220628111644.

References

Wcislo-Dziadecka D, Zbiciak-Nylec M, Brzezinska-Wcislo L, Bebenek K, Kazmierczak A . Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors. Dermatol Ther. 2017; 30(6). DOI: 10.1111/dth.12555. View

Sereflican B, Goksugur N, Bugdayci G, Polat M, Parlak A . Serum Visfatin, Adiponectin, and Tumor Necrosis Factor Alpha (TNF-α) Levels in Patients with Psoriasis and their Correlation with Disease Severity. Acta Dermatovenerol Croat. 2016; 24(1):13-9. View

Webb K, Tung R, Winterfield L, Gottlieb A, Eby J, Henning S . Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo. Br J Dermatol. 2015; 173(3):641-50. PMC: 4583813. DOI: 10.1111/bjd.14016. View

Zhu J, Wang F, Wang H, Dong N, Zhu X, Wu Y . TNF-α mRNA is negatively regulated by microRNA-181a-5p in maturation of dendritic cells induced by high mobility group box-1 protein. Sci Rep. 2017; 7(1):12239. PMC: 5612954. DOI: 10.1038/s41598-017-12492-3. View

Tome M, Lopez-Romero P, Albo C, Sepulveda J, Fernandez-Gutierrez B, Dopazo A . miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ. 2010; 18(6):985-95. PMC: 3131940. DOI: 10.1038/cdd.2010.167. View

Huang R, Li L, Wang M, Chen X, Huang Q, Lu C . An Exploration of the Role of MicroRNAs in Psoriasis: A Systematic Review of the Literature. Medicine (Baltimore). 2015; 94(45):e2030. PMC: 4912302. DOI: 10.1097/MD.0000000000002030. View

Chen H, Wang X, Bai J, He A . Expression, regulation and function of miR-495 in healthy and tumor tissues. Oncol Lett. 2017; 13(4):2021-2026. PMC: 5403365. DOI: 10.3892/ol.2017.5727. View

Korobowicz A . [Biology of tumor necrosis factor type alpha (TNF-alpha)]. Pol Merkur Lekarski. 2007; 21(124):358-61. View

Wcislo-Dziadecka D, Grabarek B, Zmarzly N, Skubis A, Sikora B, Kruszniewska-Rajs C . Influence of Adalimumab on the Expression Profile of Genes Associated with the Histaminergic System in the Skin Fibroblasts In Vitro. Biomed Res Int. 2018; 2018:1582173. PMC: 5816894. DOI: 10.1155/2018/1582173. View

10.

Wang F, Schwarz B, Graham W, Wang Y, Su L, Clayburgh D . IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology. 2006; 131(4):1153-63. PMC: 1693969. DOI: 10.1053/j.gastro.2006.08.022. View

11.

Hawkes J, Nguyen G, Fujita M, Florell S, Callis Duffin K, Krueger G . microRNAs in Psoriasis. J Invest Dermatol. 2016; 136(2):365-371. DOI: 10.1038/JID.2015.409. View

12.

Bosman F, Yan P . [Molecular pathology of colon cancer]. Pol J Pathol. 2015; 65(4 Suppl 1):S1-11. View

13.

Ovejero-Benito M, Prieto-Perez R, Llamas-Velasco M, Munoz-Aceituno E, Reolid A, Saiz-Rodriguez M . Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. Pharmacogenomics. 2017; 19(1):7-16. DOI: 10.2217/pgs-2017-0143. View

14.

Bartelds G, Krieckaert C, Nurmohamed M, van Schouwenburg P, Lems W, Twisk J . Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011; 305(14):1460-8. DOI: 10.1001/jama.2011.406. View

15.

Lis K, Kuzawinska O, Balkowiec-Iskra E . Tumor necrosis factor inhibitors - state of knowledge. Arch Med Sci. 2015; 10(6):1175-85. PMC: 4296073. DOI: 10.5114/aoms.2014.47827. View

16.

Liu M, Wang Z, Yang S, Zhang W, He S, Hu C . TNF-α is a novel target of miR-19a. Int J Oncol. 2011; 38(4):1013-22. DOI: 10.3892/ijo.2011.924. View

17.

Papaconstantinou I, Kapizioni C, Legaki E, Xourgia E, Karamanolis G, Gklavas A . Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn's disease. World J Gastrointest Pharmacol Ther. 2017; 8(4):193-200. PMC: 5680166. DOI: 10.4292/wjgpt.v8.i4.193. View

18.

Castro-Villegas C, Perez-Sanchez C, Escudero A, Filipescu I, Verdu M, Ruiz-Limon P . Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα. Arthritis Res Ther. 2015; 17:49. PMC: 4377058. DOI: 10.1186/s13075-015-0555-z. View

19.

Chen B, She S, Li D, Liu Z, Yang X, Zeng Z . Role of miR-19a targeting TNF-α in mediating ulcerative colitis. Scand J Gastroenterol. 2013; 48(7):815-24. DOI: 10.3109/00365521.2013.800991. View

20.

Mansour A . Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007; 91(3):274-6. PMC: 1857669. DOI: 10.1136/bjo.2006.108050. View